Novel natural structure corrector of apoe4 for checking alzheimer's disease: Benefits from high throughput screening and molecular dynamics simulations

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Goyal, Manisha ^a   Grover, Sonam ^b   Dhanjal, Jaspreet Kaur ^c   Goyal, Sukriti ^a   Tyagi, Chetna ^a   Chacko, Sajeev ^d   Grover, Abhinav ^b  

^a BANASTHALI UNIVERSITY   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c DELHI TECHNOLOGICAL UNIVERSITY   (India)

^d S N BOSE NATIONAL CENTRE FOR BASIC SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 IMIDAZOLEACETIC ACID; APOLIPOPROTEIN E4; ARGININE; LIGAND; PYRIDOXINE; ZINC DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LIPOPHILICITY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR WEIGHT; PROTEIN STRUCTURE; BINDING SITE; CHEMISTRY; ENZYME ACTIVE SITE; METABOLISM; PATHOLOGY; PROTEIN CONFORMATION;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BINDING SITES; CATALYTIC DOMAIN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTEIN CONFORMATION; ZINC COMPOUNDS;

EID: 84890052033     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/620793     Document Type: Article

References (48)

1. Alzheimer's Association: Alzheimer's disease facts and figures. Alzheimer's & Dementia 2012 8 1 67
2. Mathuranath P. S., George A., Ranjith N., Incidence of Alzheimer's disease in India: a 10 years follow-up study. Neurology India 2012 60 6 625 630 10.4103/0028-3886.105198
3. Sadowski M. J., Pankiewicz J., Scholtzova H., Mehta P. D., Prelli F., Quartermain D., Wisniewski T., Blocking the apolipoprotein E/amyloid- β interaction as a potential therapeutic approach for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2006 103 49 18787 18792 2-s2.0-33845484383 10.1073/pnas.0604011103 (Pubitemid 44913488)
4. Price D. L., Borchlet D. R., Martin L. J., Crain B. J., Sisodiya S. S., Troncoso J. C., Markesbery W. R., Neuropathology of Alzheimer's disease and animal models. Neuropathology of Dementing Disorders 1998 121 141
5. Conway E. L., A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations. Clinical Neuropharmacology 1998 21 1 8 17 2-s2.0-0031936729 (Pubitemid 28078330)
6. Gracon S. I., Knapp M. J., Berghoff W. G., Pierce M., DeJong R., Lobbestael S. J., Symons J., Dombey S. L., Luscombe F. A., Kraemer D., Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Disease and Associated Disorders 1998 12 2 93 101 2-s2.0-20244370995 (Pubitemid 29108216)
7. Mayeux R., Sano M., Treatment of Alzheimer's disease. The New England Journal of Medicine 1999 341 22 1670 1679 2-s2.0-0033604631 10.1056/ NEJM199911253412207
8. Ostrov D. A., Hernández Prada J. A., Corsino P. E., Finton K. A., Le N., Rowe T. C., Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening. Antimicrobial Agents and Chemotherapy 2007 51 10 3688 3698 2-s2.0-34948830988 10.1128/AAC.00392-07 (Pubitemid 47519360)
9. Lleó A., Greenberg S. M., Growdon J. H., Current pharmacotherapy for Alzheimer's disease. Annual Review of Medicine 2006 57 513 533 2-s2.0-31144450053 10.1146/annurev.med.57.121304.131442 (Pubitemid 43262005)
10. Sonkusare S. K., Kaul C. L., Ramarao P., Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacological Research 2005 51 1 1 17 2-s2.0-7044231698 10.1016/j.phrs.2004.05.005 (Pubitemid 39425068)
11. Weisgraber K. H., Apolipoprotein E: structure-function relationships. Advances in Protein Chemistry 1994 45 249 302 2-s2.0-0028303072 (Pubitemid 24139890)
12. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D., Apolipoprotein E: high-avidity binding to β -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1993 90 5 1977 1981 2-s2.0-0027407565 (Pubitemid 23069980)
13. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993 261 5123 921 923 2-s2.0-0027194791 (Pubitemid 23275809)
14. Mahley R. W., Weisgraber K. H., Huang Y., Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2006 103 15 5644 5651 2-s2.0-33645808672 10.1073/pnas.0600549103
15. Mahley R. W., Weisgraber K. H., Huang Y., Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. Journal of Lipid Research 2009 supplement 50 S183 S188 2-s2.0-66349085616 10.1194/jlr.R800069-JLR200
16. Mahley R. W., Huang Y., Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches. Annals of Neurology 2009 65 6 623 625 2-s2.0-67650076604 10.1002/ana.21736
17. Kim J., Basak J. M., Holtzman D. M., The role of apolipoprotein E in Alzheimer's disease. Neuron 2009 63 3 287 303 2-s2.0-68249134074 10.1016/j.neuron.2009.06.026
18. Dong L.-M., Wilson C., Wardell M. R., Simmons T., Mahley R. W., Weisgraber K. H., Agard D. A., Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. Journal of Biological Chemistry 1994 269 35 22358 22365 2-s2.0-0028092997
19. Dong L.-M., Weisgraber K. H., Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. Journal of Biological Chemistry 1996 271 32 19053 19057 2-s2.0-0029766916 10.1074/jbc.271.32.19053 (Pubitemid 26271562)
20. Farrer L. A., Cupples L. A., Haines J. L., Hyman B., Kukull W. A., Mayeux R., Myers R. H., Pericak-Vance M. A., Risch N., van Duijn C. M., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. Journal of the American Medical Association 1997 278 16 1349 1356 2-s2.0-0030823158 (Pubitemid 27449696)
21. Mahley R. W., Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988 240 4852 622 630 2-s2.0-0024299370
22. Mahley R. W., Rall S. C. Jr., Apolipoprotein E: far more than a lipid transport protein. Annual Review of Genomics and Human Genetics 2000 1 2000 507 537 2-s2.0-0034575124
23. Weisgraber K. H., Mahley R. W., Human apolipoprotein E: the Alzheimer's disease connection. FASEB Journal 1996 10 13 1485 1494 2-s2.0-0029844205 (Pubitemid 26384445)
24. Tanzi R. E., Bertram L., Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005 120 4 545 555 2-s2.0-13944276825 10.1016/j.cell.2005.02.008 (Pubitemid 40269768)
25. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002 297 5580 353 356 2-s2.0-0037135111 10.1126/science.1072994 (Pubitemid 34790756)
26. Blennow K., de Leon M. J., Zetterberg H., Alzheimer's disease. The Lancet 2006 368 9533 387 403 2-s2.0-33746310315 10.1016/S0140-6736(06)69113-7 (Pubitemid 44108123)
27. Risner M. E., Saunders A. M., Altman J. F. B., Ormandy G. C., Craft S., Foley I. M., Zvartau-Hind M. E., Hosford D. A., Roses A. D., Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics Journal 2006 6 4 246 254 2-s2.0-33745266146 10.1038/sj.tpj.6500369 (Pubitemid 44137951)
28. Huang Y., Mahley R. W., Commentary on "perspective on a pathogenesis and treatment of Alzheimer's disease." Apolipoprotein E and the mitochondrial metabolic hypothesis. Alzheimer's & Dementia 2006 2 2 71 73 2-s2.0-33645814057 10.1016/j.jalz.2005.12.006
29. Roses A. D., Saunders A. M., Perspective on a pathogenesis and treatment of Alzheimer's disease. Alzheimer's & Dementia 2006 2 2 59 70 2-s2.0-32544455210 10.1016/j.jalz.2005.12.001
30. Saunders A. M., Trowers M. K., Shimkets R. A., Blakemore S., Crowther D. J., Mansfield T. A., Wallace D. M., Strittmatter W. J., Roses A. D., The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochimica et Biophysica Acta 2000 1502 1 85 94 2-s2.0-0034718159 10.1016/S0925-4439(00)00035-1 (Pubitemid 30433858)
31. Reiman E. M., Caselli R. J., Chen K., Alexander G. E., Bandy D., Frost J., Declining brain activity in cognitively normal apolipoprotein E ε 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2001 98 6 3334 3339 2-s2.0-0035853154 10.1073/pnas.061509598 (Pubitemid 32220846)
32. Reiman E. M., Chen K., Alexander G. E., Caselli R. J., Bandy D., Osborne D., Saunders A. M., Hardy J., Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proceedings of the National Academy of Sciences of the United States of America 2004 101 1 284 289 2-s2.0-0347719366 10.1073/pnas.2635903100 (Pubitemid 38084242)
33. Saunders A. M., Strittmatter W. J., Schmechel D., St. George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., Rosi B. L., Gusella J. F., Crapper-MacLachlan D. R., Alberts M. J., Hulette C., Crain B., Goldgaber D., Roses A. D., Association of apolipoprotein E allele ε 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993 43 8 1467 1472 2-s2.0-0027327267 (Pubitemid 23230526)
34. Pericak-Vance M. A., Yamaoka L. H., Haynes C. S., Speer M. C., Haines J. L., Gaskell P. C., Hung W.-Y., Clark C. M., Heyman A. L., Trofatter J. A., Eisenmenger J. P., Gilbert J. R., Lee J. E., Alberts M. J., Dawson D. V., Bartlett R. J., Earl N. L., Siddique T., Vance J. M., Genetic linkage studies in Alzheimer's disease families. Experimental Neurology 1988 102 3 271 279 2-s2.0-0024203266 (Pubitemid 19005589)
35. Ye S., Huang Y., Müllendorff K., Dong L., Giedt G., Meng E. C., Cohen F. E., Kuntz I. D., Weisgraber K. H., Mahley R. W., Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America 2005 102 51 18700 18705 2-s2.0-29444460533 10.1073/pnas.0508693102 (Pubitemid 43011289)
36. Chen H.-K., Liu Z., Meyer-Franke A., Brodbeck J., Miranda R. D., McGuire J. G., Pleiss M. A., Ji Z.-S., Balestra M. E., Walker D. W., Xu Q., Jeong D.-E., Budamagunta M. S., Voss J. C., Freedman S. B., Weisgraber K. H., Huang Y., Mahley R. W., Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. Journal of Biological Chemistry 2012 287 8 5253 5266 2-s2.0-84857305241 10.1074/jbc.M111.276162
37. Protein Data Bank. http://www.rcsb.org/pdb/home/home.do
38. Schrodinger, Maestro 2009 version 9 New York, NY, USA LLC
39. Sreeramulu S., Jonker H. R. A., Langer T., Richter C., Lancaster C. R. D., Schwalbe H., The human Cdc37 · Hsp90 complex studied by heteronuclear NMR spectroscopy. Journal of Biological Chemistry 2009 284 6 3885 3896 2-s2.0-63549083573 10.1074/jbc.M806715200
40. Halgren T. A., Murphy R. B., Friesner R. A., Beard H. S., Frye L. L., Pollard W. T., Banks J. L., Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry 2004 47 7 1750 1759 2-s2.0-1642310340 10.1021/jm030644s (Pubitemid 38380918)
41. Friesner R. A., Banks J. L., Murphy R. B., Halgren T. A., Klicic J. J., Mainz D. T., Repasky M. P., Knoll E. H., Shelley M., Perry J. K., Shaw D. E., Francis P., Shenkin P. S., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry 2004 47 7 1739 1749 2-s2.0-12144289984 10.1021/jm0306430 (Pubitemid 38380917)
42. Frieden C., Garai K., Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2012 109 23 8913 8918 10.1073/pnas.1207022109
43. Irwin J. J., Shoichet B. K., ZINC-a free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling 2005 45 1 177 182 2-s2.0-13844312649 10.1021/ci049714+ (Pubitemid 40736970)
44. Schrodinger, Ligprep 2009 version 2.3 New York, NY, USA LLC
45. Schrodinger, Glide 2009 version 5.5 New York, NY, USA LLC
46. Sándor M., Kiss R., Keseru G. M., Virtual fragment docking by glide: a validation study on 190 protein-fragment complexes. Journal of Chemical Information and Modeling 2010 50 6 1165 1172 2-s2.0-77954036921 10.1021/ci1000407
47. van der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A. E., Berendsen H. J. C., GROMACS: fast, flexible, and free. Journal of Computational Chemistry 2005 26 16 1701 1718 2-s2.0-27344454932 10.1002/jcc.20291 (Pubitemid 43076182)
48. Case D. A., Darden T. A., Cheatham T. E., AMBER 12 2012 San Francisco, Calif, USA University of California